A Phase 3 interventional study of Atrasentan and Placebo in Diabetic Nephropathy, sponsored by AbbVie. Terminated. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2019-04-24.
Sponsored by AbbVie · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The study objective was to evaluate the effect of atrasentan compared with placebo on time to doubling of serum creatinine (DBSC) or the onset of end-stage renal disease (ESRD) in participants with type 2 diabetes and nephropathy who were treated with the maximum tolerated labeled daily dose (MTLDD) of a renin-angiotensin system (RAS) inhibitor. In addition, the study assessed the effects of atrasentan compared with placebo on cardiovascular (CV) morbidity and mortality, urine albumin excretion, changes in estimated glomerular filtration rate (eGFR), as well as the impact on quality of life in participants with type 2 diabetes and nephropathy.
This was a Phase 3, prospective, randomized, double-blind, enriched-population, placebo controlled, multicenter study in adult participants with type 2 diabetes and nephropathy. Participants who met the inclusion criteria for initial study entry and none of the exclusion criteria were eligible to proceed to the Run-In Period to optimize RAS inhibitor and diuretic doses. Following the Run-In Period, eligible participants entered the 6-week Enrichment Period in which all received atrasentan to determine their urinary albumin to creatinine ratio (UACR) response and to assess tolerability of atrasentan. Responders and nonresponders were then randomly assigned to receive atrasentan or placebo in the Double-Blind Treatment Period. The study was performed in 5 to 6 periods in the following sequence: Pre-Screening Period (optional); Screening Period (Visits S1 and S2); Run-In Period (up to 12 weeks; Visits R1 to R6); Enrichment Period (6 weeks; Visits E1 to E5); Double-Blind Treatment Period (randomization to final treatment visit); and Follow-Up Period (Final Treatment to F1 visit [45 days post treatment] and other post-treatment visits). The study was prematurely discontinued because of a lower than expected event rate for the renal composite endpoint, which was adjudicated by a blinded independent events adjudication committee (EAC).
543 studies on the registry are indexed under Diabetic Nephropathies; 110 are open to participants now.
This study's enrollment of 5,107 is above the median of 78 across 388 interventional studies indexed under Diabetic Nephropathies.
Browse Diabetic Nephropathies studies →AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For entry into the Run-In Period the participant must have satisfied the following criteria based on the Screening laboratory values:
For entry into the Enrichment Period the participant must have satisfied the following criteria based on the last visit of the Run-In Period:
For entry into the Double-Blind Treatment Period, participants must have satisfied the following criteria based on the last visit of the Enrichment Period:
Exclusion Criteria:
A participant was not eligible for entry into the Run-in Period if he/she met any of the following criteria:
Participant had cerebrovascular disease (CVD) or coronary artery disease (CAD) within 3 months prior to the Screening S1 visit, defined as one of the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
0.75 mg atrasentan once daily by mouth for up to 52 months
Drug: Atrasentan
Placebo once daily by mouth for up to 52 months
Drug: Placebo
Film-coated tablet
Also known as: ABT-627
Film-coated tablet
Time to the First Occurrence of a Component of the Composite Renal Endpoint in the Intent-to-Treat (ITT) Responder Set (as Randomized)
Time to the first occurrence of a component of the composite renal endpoint was defined as doubling of serum creatinine (confirmed by a 30-day serum creatinine measurement) or the onset of end stage renal disease (estimated glomerular filtration rate \[eGFR\] less than 15 ml/min/1.73 m\^2 confirmed by a 90-day eGFR measurement, receiving chronic dialysis, renal transplantation, or renal death). Only events adjudicated by the Events Adjudication Committee (EAC) were considered in defining this endpoint. Data are presented as number of participants with a primary renal composite event (first event per participant).
Time frame: From randomization to individual end of observation, up to 53 months
Time to a 50% Estimated Glomerular Filtration Rate Reduction in the Intent-to-Treat (ITT) Responder Set (as Randomized)
The event of interest for this outcome was a 50% reduction in a participant's estimated glomerular filtration rate (eGFR) value as compared to baseline, confirmed by a repeated value at least 20 days apart. The event time was defined as the first time that a 50% reduction in eGFR was observed. Data are presented as number of participants with a 50% reduction in eGFR (first event per participant).
Time frame: From randomization to individual end of observation, up to 53 months
Time to Cardio-renal Composite Endpoint in the Intent-to-Treat (ITT) Responder Set (as Randomized)
The composite event of interest for this outcome consisted of doubling of serum creatinine, end-stage renal disease (ESRD), cardiovascular (CV) death (including CV death and presumed CV death), nonfatal myocardial infarction (MI; heart attack) and nonfatal stroke. Presumed sudden cardiac death was included as a subcategory of presumed CV death. Only events adjudicated by the Events Adjudication Committee (EAC) were considered in defining this endpoint. Data are presented as number of participants with a cardio-renal composite event (first event per participant).
Time frame: From randomization to individual end of observation, up to 53 months
Time to First Occurrence of a Component of Composite Renal Endpoint for All Randomized Participants (Pooled)
Time to the first occurrence of a component of the composite renal endpoint was defined as doubling of serum creatinine (confirmed by a 30-day serum creatinine measurement) or the onset of end stage renal disease (estimated glomerular filtration rate \[eGFR\] less than 15 ml/min/1.73 m\^2 confirmed by a 90-day eGFR measurement, receiving chronic dialysis, renal transplantation, or renal death). Data for all randomized participants were pooled by treatment and analyzed. Data are presented as number of participants with a renal composite event (first event per participant).
Time frame: From randomization to individual end of observation, up to 53 months
Time to the Cardiovascular Composite Endpoint in the Intent-to-Treat (ITT) Responder Set (as Randomized)
The composite event of interest for this outcome was cardiovascular (CV) death (CV death, presumed CV death), nonfatal myocardial infarction (MI; heart attack), and nonfatal stroke. Presumed sudden cardiac death was included as a sub-category of presumed CV death. Only events adjudicated by the Events Adjudication Committee (EAC) were used. Data are presented as number of participants with a cardiovascular composite event (first event per participant).
Time frame: From randomization to individual end of observation, up to 53 months
| Milestone | Intent-to-Treat (ITT) Responder Atrasentan | Intent-to-Treat (ITT) Responder Placebo | Intent-to-Treat (ITT) Non-responder Atrasentan | Intent-to-Treat (ITT) Non-responder Placebo |
|---|---|---|---|---|
| Started | 1325 | 1323 | 509 | 511 |
| Completed | 1144 | 1131 | 411 | 418 |
| Not completed | 181 | 192 | 98 | 93 |
| Withdrew: Adverse event | 58 | 50 | 23 | 28 |
| Withdrew: Withdrew consent | 71 | 93 | 46 | 27 |
| Withdrew: Lost to follow-up | 17 | 26 | 11 | 14 |
| Withdrew: Deterioration of medical status | 3 | 4 | 3 | 7 |
| Withdrew: Investigator request | 3 | 4 | 2 | 6 |
| Withdrew: Other, not specified | 29 | 15 | 13 | 11 |
Time to the first occurrence of a component of the composite renal endpoint was defined as doubling of serum creatinine (confirmed by a 30-day serum creatinine measurement) or the onset of end stage renal disease (estimated glomerular filtration rate \[eGFR\] less than 15 ml/min/1.73 m\^2 confirmed by a 90-day eGFR measurement, receiving chronic dialysis, renal transplantation, or renal death). Only events adjudicated by the Events Adjudication Committee (EAC) were considered in defining this endpoint. Data are presented as number of participants with a primary renal composite event (first event per participant).
| Participants | Intent-to-Treat (ITT) Responder Atrasentan | Intent-to-Treat (ITT) Responder Placebo |
|---|---|---|
| Time to the First Occurrence of a Component of the Composite Renal Endpoint in the Intent-to-Treat (ITT) Responder Set (as Randomized) | 79 | 105 |
The event of interest for this outcome was a 50% reduction in a participant's estimated glomerular filtration rate (eGFR) value as compared to baseline, confirmed by a repeated value at least 20 days apart. The event time was defined as the first time that a 50% reduction in eGFR was observed. Data are presented as number of participants with a 50% reduction in eGFR (first event per participant).
| Participants | Intent-to-Treat (ITT) Responder Atrasentan | Intent-to-Treat (ITT) Responder Placebo |
|---|---|---|
| Time to a 50% Estimated Glomerular Filtration Rate Reduction in the Intent-to-Treat (ITT) Responder Set (as Randomized) | 78 | 88 |
The composite event of interest for this outcome consisted of doubling of serum creatinine, end-stage renal disease (ESRD), cardiovascular (CV) death (including CV death and presumed CV death), nonfatal myocardial infarction (MI; heart attack) and nonfatal stroke. Presumed sudden cardiac death was included as a subcategory of presumed CV death. Only events adjudicated by the Events Adjudication Committee (EAC) were considered in defining this endpoint. Data are presented as number of participants with a cardio-renal composite event (first event per participant).
| Participants | Intent-to-Treat (ITT) Responder Atrasentan | Intent-to-Treat (ITT) Responder Placebo |
|---|---|---|
| Time to Cardio-renal Composite Endpoint in the Intent-to-Treat (ITT) Responder Set (as Randomized) | 147 | 172 |
Time to the first occurrence of a component of the composite renal endpoint was defined as doubling of serum creatinine (confirmed by a 30-day serum creatinine measurement) or the onset of end stage renal disease (estimated glomerular filtration rate \[eGFR\] less than 15 ml/min/1.73 m\^2 confirmed by a 90-day eGFR measurement, receiving chronic dialysis, renal transplantation, or renal death). Data for all randomized participants were pooled by treatment and analyzed. Data are presented as number of participants with a renal composite event (first event per participant).
| Participants | Intent-to-Treat (ITT) Atrasentan | Intent-to-Treat Placebo |
|---|---|---|
| Time to First Occurrence of a Component of Composite Renal Endpoint for All Randomized Participants (Pooled) | 152 | 192 |
The composite event of interest for this outcome was cardiovascular (CV) death (CV death, presumed CV death), nonfatal myocardial infarction (MI; heart attack), and nonfatal stroke. Presumed sudden cardiac death was included as a sub-category of presumed CV death. Only events adjudicated by the Events Adjudication Committee (EAC) were used. Data are presented as number of participants with a cardiovascular composite event (first event per participant).
| Participants | Intent-to-Treat (ITT) Responder Atrasentan | Intent-to-Treat (ITT) Responder Placebo |
|---|---|---|
| Time to the Cardiovascular Composite Endpoint in the Intent-to-Treat (ITT) Responder Set (as Randomized) | 72 | 81 |
Collected over Treatment-emergent adverse events (TEAEs) and serious adverse events (TESAEs) were reported from the time of study drug administration until 45 days after the last dose of study drug (up to 24 weeks for the All Atrasentan Set in the Enrichment Period; up to 54 months for the ITT sets in the Double-Blind Period). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Enrichment Atrasentan | 25/5,107 (0.5%) | 292/5,107 (5.7%) | 1,781/5,107 (34.9%) |
| Double-Blind Atrasentan | 84/1,829 (4.6%) | 685/1,829 (37.5%) | 1,043/1,829 (57%) |
| Double-Blind Placebo | 79/1,830 (4.3%) | 626/1,830 (34.2%) | 1,038/1,830 (56.7%) |
| Event | Enrichment Atrasentan | Double-Blind Atrasentan | Double-Blind Placebo |
|---|---|---|---|
| PNEUMONIAInfections and infestations | 14/5107 | 54/1829 | 41/1830 |
| ACUTE KIDNEY INJURYRenal and urinary disorders | 19/5107 | 54/1829 | 36/1830 |
| CARDIAC FAILURE CONGESTIVECardiac disorders | 22/5107 | 37/1829 | 22/1830 |
| ACUTE MYOCARDIAL INFARCTIONCardiac disorders | 7/5107 | 34/1829 | 28/1830 |
| CORONARY ARTERY DISEASECardiac disorders | 6/5107 | 29/1829 | 19/1830 |
| ANAEMIABlood and lymphatic system disorders | 7/5107 | 27/1829 | 11/1830 |
| END STAGE RENAL DISEASERenal and urinary disorders | 0/5107 | 19/1829 | 27/1830 |
| HYPOGLYCAEMIAMetabolism and nutrition disorders | 13/5107 | 22/1829 | 12/1830 |
| CELLULITISInfections and infestations | 5/5107 | 14/1829 | 22/1830 |
| URINARY TRACT INFECTIONInfections and infestations | 6/5107 | 21/1829 | 12/1830 |
| Event | Enrichment Atrasentan | Double-Blind Atrasentan | Double-Blind Placebo |
|---|---|---|---|
| OEDEMA PERIPHERALGeneral disorders | 1148/5107 | 534/1829 | 483/1830 |
| HYPERTENSIONVascular disorders | 78/5107 | 158/1829 | 218/1830 |
| ANAEMIABlood and lymphatic system disorders | 180/5107 | 216/1829 | 127/1830 |
| NASOPHARYNGITISInfections and infestations | 145/5107 | 180/1829 | 169/1830 |
| HYPERKALAEMIAMetabolism and nutrition disorders | 77/5107 | 132/1829 | 143/1830 |
| BACK PAINMusculoskeletal and connective tissue disorders | 61/5107 | 88/1829 | 125/1830 |
| HYPOGLYCAEMIAMetabolism and nutrition disorders | 126/5107 | 114/1829 | 120/1830 |
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 110/5107 | 106/1829 | 114/1830 |
| HYPERURICAEMIAMetabolism and nutrition disorders | 84/5107 | 101/1829 | 105/1830 |
| DIARRHOEAGastrointestinal disorders | 103/5107 | 99/1829 | 103/1830 |
Intent-to-Treat (ITT) Responders (participants who achieved at least 30% reduction in their albumin to creatinine ratio \[UACR\] in the Enrichment Period \[EP\]) and ITT Non-responders (Participants who achieved \< 30% reduction in their UACR in the EP)
| Age, Continuous(years) | Intent-to-Treat (ITT) Responder Atrasentan | Intent-to-Treat (ITT) Responder Placebo | Intent-to-Treat (ITT) Non-responder Atrasentan | Intent-to-Treat (ITT) Non-responder Placebo | Total |
|---|---|---|---|---|---|
| Mean | 64.9 ± 8.64 | 64.7 ± 8.66 | 63.8 ± 9.12 | 63.6 ± 8.93 | 64.5 ± 8.77 |
| Sex: Female, Male(Participants) | Intent-to-Treat (ITT) Responder Atrasentan | Intent-to-Treat (ITT) Responder Placebo | Intent-to-Treat (ITT) Non-responder Atrasentan | Intent-to-Treat (ITT) Non-responder Placebo | Total |
|---|---|---|---|---|---|
| Female | 331 | 352 | 127 | 136 | 946 |
| Male | 994 | 971 | 382 | 375 | 2722 |
| Race (NIH/OMB)(Participants) | Intent-to-Treat (ITT) Responder Atrasentan | Intent-to-Treat (ITT) Responder Placebo | Intent-to-Treat (ITT) Non-responder Atrasentan | Intent-to-Treat (ITT) Non-responder Placebo | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 30 | 29 | 7 | 10 | 76 |
| Asian | 446 | 455 | 143 | 154 | 1198 |
| Native Hawaiian or Other Pacific Islander | 9 | 9 | 7 | 3 | 28 |
| Black or African American | 73 | 76 | 36 | 39 | 224 |
| White | 753 | 744 | 313 | 300 | 2110 |
| More than one race | 14 | 10 | 3 | 5 | 32 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
No study locations are listed for this record.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from May 2013 to primary completion in Mar 2018, 58 months.
Results were first posted in Apr 2019, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Atrasentan